BI-3802 is a highly potent BCL6 degrader, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3802 has antitumor activity.

ARV-393是一种口服有效的 PROTAC，可利用泛素蛋白酶体系统、靶向降解 BCL6。ARV-393 由分别靶向 BCL6 和 E3 连接酶 cereblon 的配体耦连组成。